Biocon India
Biocon Ltd.
Building a Biotech Powerhouse
Case analysis
-Rajdeep Desai
Introduction: Established in 1978, Biocon Limited is Asia’s premier biotechnology company and India's largest biotechnology company by revenue. It is the only Asian company among the top 25 in global biopharma. Biocon is called as Poster child of Biotech in India. The Group, promoted by Ms. Kiran Mazumdar Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain extends the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human Insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM) 1. Biocon’s fully integrated business model spans the entire drug value chain, from preclinical discovery to clinical development and through to commercialization. Their businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth.
1
Biocon Press Release dated Oct 20, 2011. (http://www.biocon.com/docs/PR_201011_v1.pdf)
2
Corporate Structure of Biocon India:
Source: http://www.biocon.com/biocon_invrelation_org_structure.asp Syngene and Clinigene are the two main subsidiaries of Biocon India. Syngene is an internationally reputed contract research and manufacturing organization with multidisciplinary skills in chemistry and biology services. Clinigene International Limited is a fullservice Clinical Research Organization that partners with
Building a Biotech Powerhouse
Case analysis
-Rajdeep Desai
Introduction: Established in 1978, Biocon Limited is Asia’s premier biotechnology company and India's largest biotechnology company by revenue. It is the only Asian company among the top 25 in global biopharma. Biocon is called as Poster child of Biotech in India. The Group, promoted by Ms. Kiran Mazumdar Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain extends the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human Insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM) 1. Biocon’s fully integrated business model spans the entire drug value chain, from preclinical discovery to clinical development and through to commercialization. Their businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth.
1
Biocon Press Release dated Oct 20, 2011. (http://www.biocon.com/docs/PR_201011_v1.pdf)
2
Corporate Structure of Biocon India:
Source: http://www.biocon.com/biocon_invrelation_org_structure.asp Syngene and Clinigene are the two main subsidiaries of Biocon India. Syngene is an internationally reputed contract research and manufacturing organization with multidisciplinary skills in chemistry and biology services. Clinigene International Limited is a fullservice Clinical Research Organization that partners with